Genix Pharmaceuticals Corporation formulates, manufactures, licenses, and markets life sciences related products with a focus on nutraceuticals and pharmaceuticals in Canada. The company offers generic ophthalmic prescription products, ophthalmic nutraceutical formulations, and prescription generic drugs; ophthalmic OTC products; and eye ointments and drops. It also provides Flu-X, an anti-viral, anti-flu, and common colds coronavirus oral and spray herbal product; Rechlor, a dietary supplement to support kidney health; Sucanon, an herbal health supplement to manage blood sugar levels and enhance insulin sensitivity in non-insulin dependent adults; and Synthroid, a levothyroxine sodium drug for the treatment of hypothyroidism. The company was formerly known as Alta Natural Herbs & Supplements Ltd. and changed its name to Genix Pharmaceuticals Corporation in June 2019. Genix Pharmaceuticals Corporation was incorporated in 1993 and is based in Vancouver, Canada.…
Genix Pharmaceuticals (CVE: GENX) is listed on the TSX Venture Exchange, where its shares trade in CAD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector.
The shares were at 0.0200 CAD on 19 November 2026, down 33.3% over 52 weeks. Its 52-week range is 0.0150 CAD to 0.0300 CAD: the price is 33.3% below the high and 33.3% above the low.
Its market capitalisation is 918.36K CAD.
Genix Pharmaceuticals reports return on equity of 23.6% and an operating margin of 0.0%.
Its debt exceeds its cash by 1.14M CAD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health. The next earnings report is expected on 23 November 2026.